Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward V Loftus

Showing results (351-360 of 471) with videos related to

Pageof 48
Sort By:
Inflammatory Bowel Diseases|September 18, 2010
Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patientsJason M Swoger, Edward V Loftus, William J Tremaine, et al.
Gut|December 1, 2006
The epidemiology of microscopic colitis: a population based study in Olmsted County, MinnesotaDarrell S Pardi, Edward V Loftus, Thomas C Smyrk, et al.
Inflammatory Bowel Diseases|October 10, 2013
Comparative outcomes of younger and older hospitalized patients with inflammatory bowel disease treated with corticosteroidsNicholas K Weber, David H Bruining, Edward V Loftus, et al.
The American Journal of Gastroenterology|June 20, 2008
Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel diseaseJoanna M Peloquin, Darrell S Pardi, William J Sandborn, et al.
Journal of Crohn'S & Colitis|February 4, 2024
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative ColitisSubrata Ghosh, Brian G Feagan, Elyssa Ott, et al.
Journal of Crohn'S & Colitis|April 1, 2025
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitisWalter Reinisch, Edward V Loftus, Stefan Schreiber, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 26, 2016
Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune SuppressionThomas G Cotter, Nicola Gathaiya, Jelena Catania, et al.
Gastroenterology|April 19, 2006
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, MinnesotaTine Jess, Edward V Loftus, Fernando S Velayos, et al.
Abdominal Imaging|April 25, 2014
Clinical characteristics and imaging features of small bowel adenocarcinomas in Crohn's diseaseNicholas K Weber, Joel G Fletcher, Jeff L Fidler, et al.
The New England Journal of Medicine|September 26, 2019
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative ColitisBruce E Sands, Laurent Peyrin-Biroulet, Edward V Loftus, et al.
Pageof 48

Showing results (351-360 of 471) with videos related to

Sort By:
Pageof 48
Inflammatory Bowel Diseases|September 18, 2010
Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patientsJason M Swoger, Edward V Loftus, William J Tremaine, et al.
Gut|December 1, 2006
The epidemiology of microscopic colitis: a population based study in Olmsted County, MinnesotaDarrell S Pardi, Edward V Loftus, Thomas C Smyrk, et al.
Inflammatory Bowel Diseases|October 10, 2013
Comparative outcomes of younger and older hospitalized patients with inflammatory bowel disease treated with corticosteroidsNicholas K Weber, David H Bruining, Edward V Loftus, et al.
The American Journal of Gastroenterology|June 20, 2008
Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel diseaseJoanna M Peloquin, Darrell S Pardi, William J Sandborn, et al.
Journal of Crohn'S & Colitis|February 4, 2024
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative ColitisSubrata Ghosh, Brian G Feagan, Elyssa Ott, et al.
Journal of Crohn'S & Colitis|April 1, 2025
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitisWalter Reinisch, Edward V Loftus, Stefan Schreiber, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 26, 2016
Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune SuppressionThomas G Cotter, Nicola Gathaiya, Jelena Catania, et al.
Gastroenterology|April 19, 2006
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, MinnesotaTine Jess, Edward V Loftus, Fernando S Velayos, et al.
Abdominal Imaging|April 25, 2014
Clinical characteristics and imaging features of small bowel adenocarcinomas in Crohn's diseaseNicholas K Weber, Joel G Fletcher, Jeff L Fidler, et al.
The New England Journal of Medicine|September 26, 2019
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative ColitisBruce E Sands, Laurent Peyrin-Biroulet, Edward V Loftus, et al.
Pageof 48